Serine proteases, inhibitors and receptors in renal fibrosis

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 656-664

  Eddy, Allison A ^a,b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Fibrosis; Plasminogen activator inhibitor 1; Urokinase; Urokinase receptor (uPAR)

Indexed keywords

GLYCOPROTEIN; INTEGRIN; KININOGEN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VITRONECTIN;

CELL MIGRATION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DISEASE ACTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; INFLAMMATORY CELL; KIDNEY FIBROSIS; KIDNEY FUNCTION; MACROPHAGE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; URETER OBSTRUCTION;

ANIMALS; CELL MOVEMENT; CHRONIC DISEASE; FIBROBLASTS; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; KININOGENS; LDL-RECEPTOR RELATED PROTEIN 1; MACROPHAGES; MEMBRANE GLYCOPROTEINS; NEPHRITIS; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SERINE ENDOPEPTIDASES; SERPINS; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 64849116076     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-12-0779     Document Type: Conference Paper

References (86)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 2007; 298: 2038-2047.
2. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 353-365.
3. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008; 51: S1-320.
4. Neugarten J, Gallo G, Silbiger S, et al. Glomerulosclerosis in aging humans is not influenced by gender. Am J Kidney Dis 1999; 34: 884-888.
5. Levey A, Coresh J. Part 4. Definition and classification of stages of chronic kideny disease. Am J Kidney Dis 2002; 39: S46-S75.
6. Eddy AA, Fogo AB. PAI-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
7. Wang Y, Wang Y P, Zheng G, et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney international 2007; 72: 290-299.
8. Ricardo S, van Goor H, Eddy A. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522-3530.
9. Nishida M, Fujinaka H, Matsusaka T, et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 2002; 110: 1859-1868.
10. Zhang G, Kim H, Cai X, et al. Urokinase receptor deficiency accelerates fibrosis in obstructive nephropathy. J Am Soc Nephrol 2003; 14: 1254-1271.
11. Engelholm LH, List K, Netzel-Arnett S, et al. uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J Cell Biol 2003; 160: 1009-1015.
12. Everts V, van der Zee E, Creemers L, et al. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem J 1996; 28: 229-245.
13. Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008; 4: 216-226.
14. Nangaku M. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
15. Zandi-Nejad K, Eddy AA, Glassock RJ, et al. Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl 2004: S76-89.
16. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
17. Zeisberg M, Kalluri R. The role of epithelial-tomesenchymal transition in renal fibrosis. J Mol Med 2004; 82: 175-181.
18. Theilig F, Kriz W, Jerichow T, et al. Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury. J Am Soc Nephrol 2007; 18: 1824-1834.
19. Okamura DM, Lopez-Guisa JM, Koelsch K, et al. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol 2007; 293: F575-585.
20. Okamura DM, Pennathur S, Koelsch K, et al. CD36 regulates oxidative stress and inflammation in hypercholesterolemicchronic kidney disease. J Am Soc Nephrol 2009; epub ahead of print.
21. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
22. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. American journal of physiology 2002; 283: F209-220.
23. Reis K, Arinsoy T, Derici U, et al. Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant 2005; 19: 10-14.
24. Wang AY, Poon P, Lai FM, et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 2001; 59: 1520-1528.
25. Estelles A, Dalmau J, Falco C, et al. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost 2001; 86: 647-652.
26. Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004; 91: 425-437.
27. Hoekstra T, Geleijnse JM, Schouten EG, et al. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-872.
28. Oda T, Jung YO, Kim H, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001; 30: 587-596.
29. Matsuo S, Lopez-Guisa JM, Cai X, et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005; 67: 2221-2238.
30. Huang Y, Haraguchi M, Lawrence DA, et al. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 2003; 112: 379-388.
31. Huang Y, Border WA, Yu L, et al. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 2008; 19: 329-338.
32. Montes R, Declerck PJ, Calvo A, et al. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1. Thromb Haemost 2000; 84: 65-70.
33. Taneda S, Hudkins KL, Muhlfeld AS, et al. Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis. J Am Soc Nephrol 2008; 19: 243-251.
34. Moll S, Schaeren-Wiemers N, Wohlwend A, et al. Protease nexin 1 in the murine kidney: Glomerular localization and up-regulation in glomerulopathies. Kidney Int 1996; 50: 1936-1945.
35. Strehlow D, Jelaska A, Strehlow K, et al. A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma. J Clin Invest 1999; 103: 1179-1190.
36. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001; 108: 779-784.
37. Zhang G, Kernan KA, Collins SJ, et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 2007; 18: 846-859.
38. Romer J, Bugge TH, Pyke C, et al. Plasminogen and wound healing. Nat Med 1996; 2: 725.
39. Lyons RM, Gentry LE, Purchio AF, et al. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110: 1361-1367.
40. Oda T, Kim H, Wing D, et al. Effects of genetic PAI-1 deficiency in mice with protein-overload proteinuria. J Am Soc Nephrol 1999; 10: 578A [Abstract].
41. Gold LI, Schwimmer R, Quigley J P. Human plasma fibronectin as a substrate for human urokinase. Biochem J 1989; 262: 529-534.
42. Naldini L, Vigna E, Bardelli A, et al. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 1995; 270: 603-611.
43. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol 2004; 287: F7-16.
44. Yamaguchi I, Lopez-Guisa JM, Cai X, et al. Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol 2007; 293: F12-19.
45. Zhang G, Eddy AA. Urokinase and its receptors in chronic kidney disease. Front Biosci 2008; 13: 5462-5478.
46. Zhang G, Kernan KA, Collins SJ, et al. The novel ligand-receptor relationship identified between urokinase and the nicotinic receptor (nAChRalpha1): its signaling and function in cell growth and chronic renal injury. J Am Soc Nephrol 2007; 18: 7A.
47. Yang J, Shultz RW, Mars WM, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002; 110: 1525-1538.
48. Hu K, Wu C, Mars WM, et al. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J Clin Invest 2007; 117: 3821-3832.
49. Hu K, Lin L, Tan X, et al. tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J Am Soc Nephrol 2008; 19: 503-514.
50. Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937-1949.
51. Cochrane AL, Kett MM, Samuel CS, et al. Renal structural and functional repair in a mouse model of reversal of ureteral obstruction. J Am Soc Nephrol 2005; 16: 3623-3630.
52. Eddy A. Can renal fibrosis be reversed? Pediatr Nephrol 2005; 20: 1369-1375.
53. Kriz W, Hahnel B, Hosser H, et al. Pathways to recovery and loss of nephrons in anti-Thy-1 nephritis. J Am Soc Nephrol 2003; 14: 1904-1926.
54. Ma LJ, Nakamura S, Aldigier JC, et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005; 16: 966-976.
55. Degryse B, Neels JG, Czekay R P, et al. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004; 279: 22595-22604.
56. Zhang G, Kim H, Cai X, et al. Urokinase receptor modulates cellular and angiogenic responses in obstructive uropathy. J Am Soc Nephrol 2003; 14: 1234-1253.
57. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
58. Colman RW, Pixley RA, Najamunnisa S, et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-1487.
59. Binder BR, Mihaly J, Prager G W. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97: 336-342.
60. Wei C, Moller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14: 55-63.
61. Roelofs JJ, Rouschop KM, Teske GJ, et al. The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. Kidney Int 2006; 70: 1942-1947.
62. Sitrin RG, Pan PM, Harper HA, et al. Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J Immunol 2000; 165: 3341-3349.
63. Alfano M, Mariani SA, Elia C, et al. Ligand-engaged urokinase-type plasminogen activator receptor (uPAR) and activation of the CD11b/CD18 (Mac1) integrin inhibit late events of HIV expression in monocytic cells. Blood 2009; 113: 1699-1709.
64. Montuori N, Carriero M V, Salzano S, et al. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002; 277: 46932-46939.
65. Resnati M, Pallavicini I, Wang JM, et al. The fibrinolytic receptor for urokinase activates the G proteincoupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002; 99: 1359-1364.
66. Sitrin RG, Pan PM, Blackwood RA, et al. Cutting edge: evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils. J Immunol 2001; 166: 4822-4825.
67. Xue W, Kindzelskii AL, Todd R F, 3rd, et al. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 1994; 152: 4630-4640.
68. Shushakova N, Eden G, Dangers M, et al. The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung. J Immunol 2005; 175: 4060-4068.
69. Shushakova N, Tkachuk N, Dangers M, et al. Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci 2005; 118: 2743-2753.
70. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 2002; 383: 5-19.
71. Stefansson S, Lawrence DA. Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE 2003; 2003: pe24.
72. Mazzieri R, Blasi F. The urokinase receptor and the regulation of cell proliferation. Thromb Haemost 2005; 93: 641-646.
73. Behrendt N, Ronne E, Dano K. A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking. FEBS letters 1993; 336: 394-396.
74. L ópez-Guisa JM, Bugge TH, Isacke CH, et al. Endo180/uPAR- associated protein is an important regular of renal fibrogenesis J Am Soc Nephrol 2008; 19: 32A (Abstract).
75. Kjoller L, Engelholm LH, Hoyer-Hansen M, et al. uPARAP/endo180 directs lysosomal delivery and degradation of collagen I V. Exp Cell Res 2004; 293: 106-116.
76. Wienke D, MacFadyen JR, Isacke CM. Identification and characterization of the endocytic transmembrane glycoprotein endo180 as a novel collagen receptor. Mol Biol Cell 2003; 14: 3592-3604.
77. East L, McCarthy A, Wienke D, et al. A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake. EMBO Rep 2003; 4: 710-716.
78. Kjaergaard M, Gardsvoll H, Hirschberg D, et al. Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris. Protein Sci 2007; 16: 1934-1945.
79. Cao DJ, Guo YL, Colman RW. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circulation research 2004; 94: 1227-1234.
80. Khan MM, Bradford HN, Isordia-Salas I, et al. High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arterioscl Thromb Vasc Biol 2006; 26: 2260-2266.
81. Colman RW, Jameson BA, Lin Y, et al. Domain 5 of high molecular weight kininogen (kininostatin) downregulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-550.
82. Schanstra J P, Neau E, Drogoz P, et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110: 371-379.
83. Okada H, Watanabe Y, Kikuta T, et al. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol 2004; 15: 2404-2413.
84. Azizi M, Wuerzner G. Rationale for combining blockers of the renin-angiotensin system. Seminars Nephrol 2007; 27: 544-554.
85. Liang OD, Chavakis T, Linder M, et al. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence. Biol Chem 2003; 384: 229-236.
86. Zhang G, Cai X, Lopez-Guisa JM, et al. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein. J Am Soc Nephrol 2004; 15: 2090-2102.